LY03005

DRUG6 trials

Sponsors

Luye Pharma Group Ltd.

Conditions

Major DepressionMajor Depressive DisorderMajor Depressive Disorder, Recurrent, Unspecified

Phase 1

Safety, Tolerability and Pharmacokinetics Study of LY03005

CompletedNCT02055300

Luye Pharma Group Ltd.Major Depressive Disorder

Start: 2014-02-28End: 2014-08-31Updated: 2014-11-10

Multiple Ascending Dose Study in Healthy Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY03005

CompletedNCT02271412

Luye Pharma Group Ltd.Major Depressive Disorder, Recurrent, Unspecified

Start: 2014-10-31End: 2015-03-31Updated: 2015-10-21

Pilot BA Study of New LY03005 vs Pristiq

CompletedNCT02988024

Luye Pharma Group Ltd.Major Depression

Start: 2016-12-07End: 2016-12-28Updated: 2017-03-20

Relative Bioavailability (RBA) Study of LY03005 vs Pristiq®

CompletedNCT03357796

Luye Pharma Group Ltd.Major Depressive Disorder

Start: 2017-11-27End: 2017-12-22Updated: 2018-01-04

A Study of LY03005 vs Pristiq

CompletedNCT03733574

Luye Pharma Group Ltd.Major Depressive Disorder

Start: 2018-06-19End: 2018-07-26Updated: 2018-11-09

A Relative Bioavailability Food Effect Study of LY03005

CompletedNCT03822065

Luye Pharma Group Ltd.Major Depressive Disorder

Start: 2019-01-16End: 2019-02-16Updated: 2019-08-06